Effect of age on the immunogenicity of yeast recombinant hepatitis b vaccines containing surface antigen (s) or pres2+s antigens

Mary Lou Clements, Emil Miskovsky, Morton Davidson, Thomas Cupps, Newton Kumwenda, Laurie A. Sandman, David West, Theresa Hesley, Virginia Ioll, William Miller, Gary Calandra, Saul Krugman

Research output: Contribution to journalArticlepeer-review

Abstract

A single-blind, multicenter, phase II trial of yeast recombinant hepatitis B virus (HBV) vaccines containing surface antigen (S) alone or with PreS2 (PreS2+S) was conducted in 282 healthy HBV-seronegative adults aged 20-59 years. Each volunteer was randomly assigned to receive HBV vaccine containing 10 μg of S or one of three doses of PreS2 plus S: 2 + 10 μg, 4 + 20 μg, or 8 + 40 μg. The level of antibody to HBV surface antigen reached depended on the dose of S, not PreS2, received. In each vaccine group, volunteers 20-39 years old had higher titers of anti-PreS2 and antibody to S than those 40-59 years old. The age-related effect on immune response to HBV vaccination suggests that adults should beimmunized against hepatitis Bat as early an age as possible and that older persons may need a higher dose or booster immunizations to achieve durable immunity.

Original languageEnglish (US)
Pages (from-to)510-516
Number of pages7
JournalJournal of Infectious Diseases
Volume170
Issue number3
DOIs
StatePublished - Sep 1994

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Effect of age on the immunogenicity of yeast recombinant hepatitis b vaccines containing surface antigen (s) or pres2+s antigens'. Together they form a unique fingerprint.

Cite this